GC Biopharma’s Recombinant Anthrax Vaccine Shows Strong Phase 2 Safety and Efficacy Results
Yongin, South Korea — November 3, 2025 GC Biopharma has announced promising Phase 2 clinical trial results for its...
Vaccine Safety
Advertisement
Pfizer and BioNTech Report Strong Data for LP.8.1-Adapted COVID-19 Vaccine
NEW YORK & MAINZ, Germany – September 8, 2025 – Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)...
Novavax’s Nuvaxovid™ 2025–2026 Formula COVID-19 Vaccine Approved in the U.S.
GAITHERSBURG, Md., August 27, 2025 – The U.S. Food and Drug Administration (FDA) has granted approval for Novavax’s Nuvaxovid™...
Advertisement
